Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis (SAVE)

September 24, 2025 updated by: Miltenyi Biomedicine GmbH

Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women With Preeclampsia Via Apheresis Utilizing the Flt-1 Adsorption Column

This clinical investigation is a medical device trial to examine the safety and efficacy of TheraSorb sFlt-1 adsorber treatment of pregnant patients with preeclampsia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cologne, Germany, 50937
        • Universitätsklinikum Köln
      • Leipzig, Germany, 04103
        • Universitatsklinikum Leipzig
      • Cambridge, United Kingdom, CB2 0QQ
        • Cambridge Clinical Trials Unit, Addenbrooke's Hospital
      • Oxford, United Kingdom, OX3 9DU
        • Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Reduced criteria!

Phase 0

Inclusion Criteria:

  • Age ≥18 and ≤45 years;
  • Male or female;
  • Female subjects of childbearing potential must have a negative serum pregnancy test result at screening and practice two reliable methods of contraception throughout the study.

Exclusion Criteria:

  • Dysfunction of cerebral nervous system and/or heart disease;
  • History of preexisting chronic renal disease;
  • Treatment with ACE inhibitors;
  • Therapeutic full anticoagulation therapy prior to trial entry;
  • Liver abnormalities;
  • Clinically significant pulmonary edema and/or thrombocytopenia and/or anemia;
  • Active hepatitis B, C, or tuberculosis infection or HIV infection
  • Hypersensitivity to heparin and/or citrate;
  • Indications that prohibit transient anticoagulation using heparin and/or ACD-A-solutions;
  • Known intolerance to extracorporeal procedures in general or towards one of the individual excipients or towards other supporting agents;
  • Drug or alcohol abuse within the last 2 years;
  • Lack of compliance of subject;
  • History or diagnosis of severe periodontitis;

Phase A and B

Inclusion Criteria:

  • Age >18 and ≤45 years ;
  • Pregnant woman with pre-term preeclampsia
  • sFlt-1/PlGF ratio ≥85 ;
  • sFlt-1 level of ≥ 8000pg/mL

Exclusion Criteria:

Maternal exclusion criteria

  • History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease;
  • History of preexisting chronic renal disease (CKD stage >3a, eGFR ≤45ml/min/1.73m²);
  • Treatment with ACE inhibitors;
  • Therapeutic full anticoagulation therapy prior to trial entry;
  • Signs or history of clinically significant cerebral nervous system dysfunction;
  • History of clinically significant liver abnormalities;
  • Clinically significant pulmonary edema and/or thrombocytopenia and/or anemia;
  • Active hepatitis B, C, tuberculosis infection or HIV-positive status;
  • Any condition that the investigator deems a risk to the patient or fetus in completing the trial;
  • Indications that prohibit transient anticoagulation using heparin and/or ACD-A-solutions;
  • Drug or alcohol abuse within the last 2 years;
  • Lack of compliance of patient;
  • Known intolerance to extracorporeal procedures in general or to one of the excipients or other supporting agents;
  • Hypersensitivity to heparin and/or citrate;
  • < 30 0/7 weeks of gestation and abnormal CTG and/or abnormal Ductus venosus Doppler flow,
  • ≥30 0/7 weeks of gestation and Doppler evidence of umbilical artery Absent or Reversed End-Diastolic Velocity (AREDV);
  • Various Placental exclusion criteria;
  • Multiple pregnancy
  • History or diagnosis of severe periodontitis

Fetal exclusion criteria

  • Any known trisomy;
  • Amniotic fluid index <5cm (greatest single pocket <2cm);
  • Estimated fetal weight <3rd percentile for gestational age;
  • Fetus which are at high risk of heart disease;
  • Fetus with congenital heart defect;
  • Fetal signs of bleeding;
  • Hydrops fetalis;
  • Pathological fetal Doppler flow of the ductus venosus (absent A-wave in two measurements);
  • Evidence of severe fetal malformations;
  • Known infection of fetus;
  • Known severe anemia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Phase 0 - healthy volunteers
Phase 0 is an initial safety phase where subjects will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
Experimental: Phase A - preeclampsia patients
Phase A is a safety and dose-finding phase during which pregnant women diagnosed with preeclampsia will undergo one single TheraSorb sFlt-1 adsorber apheresis procedure.
Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
Experimental: Phase B - preeclampsia patients
Phase B is a safety and efficacy phase during which pregnant women diagnosed with preeclampsia will undergo TheraSorb sFlt-1 adsorber apheresis procedures up to twice weekly.
Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Occurrence of AEs and SAEs in healthy volunteers until the 2 weeks follow-up (Phase 0)
Time Frame: until 2 weeks post treatment
until 2 weeks post treatment
Occurrence of AEs and SAEs in pregnant subjects and the fetus or infant until the 6 weeks post-delivery visit is reached (Phase A-B).
Time Frame: until 6 weeks post delivery
until 6 weeks post delivery

Secondary Outcome Measures

Outcome Measure
Time Frame
Phase 0: Determine changes of sFlt-1 levels.
Time Frame: until 2 weeks post treatment
until 2 weeks post treatment
Phase 0: Complement activation levels pre-, during and post apheresis.
Time Frame: Before, during and directly following the performance of the single apheresis treatment (1 day)
Before, during and directly following the performance of the single apheresis treatment (1 day)
Phase 0: Concentration of antibody leaching during an apheresis procedure
Time Frame: During an apheresis procedure (1 day)
During an apheresis procedure (1 day)
Phase 0: Change of HAMA levels in pre- and post apheresis blood
Time Frame: until 2 weeks post treatment
until 2 weeks post treatment
Phase 0: Evaluate blood pressure values
Time Frame: until 2 weeks post treatment
until 2 weeks post treatment
Phase 0: Evaluate spot urine values
Time Frame: until 2 weeks post treatment
until 2 weeks post treatment
Phase A/B: Occurrence of SAEs in the one year follow-up period
Time Frame: until end of FU, (1 year)
until end of FU, (1 year)
Phases A/B: Evaluate antibody leaching in phase A.
Time Frame: During the performance of the single apheresis treatment in Phase A (1 day) as well as pre and 3hrs post apheresis
During the performance of the single apheresis treatment in Phase A (1 day) as well as pre and 3hrs post apheresis
Phases A and B: Evaluate maternal sFlt-1 levels.
Time Frame: Constant measures throughout the trial until delivery (up to 19 weeks)
Constant measures throughout the trial until delivery (up to 19 weeks)
Phases A/B: Evaluate the sFlt-1/PlGF ratio.
Time Frame: Constant measures throughout the trial until delivery (up to 19 weeks)
Constant measures throughout the trial until delivery (up to 19 weeks)
Phases A/B:Evaluate neonatal umbilical cord blood sFlt-1 levels at birth.
Time Frame: at birth
at birth
Phases A/B: Determine HAMA levels
Time Frame: until 6 week FU visit
until 6 week FU visit
Phases A/B: Time and method of delivery, and anesthesia administered
Time Frame: at birth
at birth
Phases A and B: Determine the post-partum maternal and neonatal length of hospitalization.
Time Frame: Following birth up to one year
Following birth up to one year
Phases A/B: Evaluate standard markers of fetal development throughout pregnancy.
Time Frame: From start of trial until delivery (up to 19 weeks)
From start of trial until delivery (up to 19 weeks)
Phases A/B: Evaluate standard markers of neonatal development.
Time Frame: Directly following delivery until end of FU (1 year)
Directly following delivery until end of FU (1 year)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Thomas Benzing, Prof. Dr., University Clinic Cologne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2016

Primary Completion (Actual)

August 20, 2024

Study Completion (Actual)

July 16, 2025

Study Registration Dates

First Submitted

September 19, 2016

First Submitted That Met QC Criteria

October 3, 2016

First Posted (Estimated)

October 4, 2016

Study Record Updates

Last Update Posted (Estimated)

September 30, 2025

Last Update Submitted That Met QC Criteria

September 24, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe